Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
TKMR's Cash to Debt is ranked higher than
91% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. TKMR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
TKMR' s 10-Year Cash to Debt Range
Min: 178.64  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.75
TKMR's Equity to Asset is ranked higher than
58% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TKMR: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
TKMR' s 10-Year Equity to Asset Range
Min: 0.03  Med: 0.75 Max: 0.9
Current: 0.75
0.03
0.9
Interest Coverage No Debt
TKMR's Interest Coverage is ranked higher than
85% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TKMR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TKMR' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 1.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -296.09
TKMR's Operating margin (%) is ranked lower than
66% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. TKMR: -296.09 )
Ranked among companies with meaningful Operating margin (%) only.
TKMR' s 10-Year Operating margin (%) Range
Min: -22383.33  Med: -102.68 Max: 16.57
Current: -296.09
-22383.33
16.57
Net-margin (%) -215.99
TKMR's Net-margin (%) is ranked lower than
63% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. TKMR: -215.99 )
Ranked among companies with meaningful Net-margin (%) only.
TKMR' s 10-Year Net-margin (%) Range
Min: -19172.92  Med: -121.56 Max: 209.94
Current: -215.99
-19172.92
209.94
ROE (%) -16.62
TKMR's ROE (%) is ranked higher than
60% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. TKMR: -16.62 )
Ranked among companies with meaningful ROE (%) only.
TKMR' s 10-Year ROE (%) Range
Min: -1231.61  Med: -40.47 Max: 128.4
Current: -16.62
-1231.61
128.4
ROA (%) -12.62
TKMR's ROA (%) is ranked higher than
61% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. TKMR: -12.62 )
Ranked among companies with meaningful ROA (%) only.
TKMR' s 10-Year ROA (%) Range
Min: -61.09  Med: -32.46 Max: 147.42
Current: -12.62
-61.09
147.42
ROC (Joel Greenblatt) (%) -2696.45
TKMR's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. TKMR: -2696.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TKMR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2104.82  Med: -568.16 Max: 2709.57
Current: -2696.45
-2104.82
2709.57
Revenue Growth (3Y)(%) -21.70
TKMR's Revenue Growth (3Y)(%) is ranked lower than
69% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. TKMR: -21.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TKMR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -27.8  Med: 4.45 Max: 236.2
Current: -21.7
-27.8
236.2
EBITDA Growth (3Y)(%) 21.80
TKMR's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. TKMR: 21.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TKMR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -3.25 Max: 38
Current: 21.8
0
38
EPS Growth (3Y)(%) 27.90
TKMR's EPS Growth (3Y)(%) is ranked higher than
82% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. TKMR: 27.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TKMR' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.1  Med: 9.70 Max: 32
Current: 27.9
-47.1
32
» TKMR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TKMR Guru Trades in Q2 2014

Jim Simons 150,200 sh (+500.80%)
» More
Q3 2014

TKMR Guru Trades in Q3 2014

Paul Tudor Jones 100,000 sh (New)
Jim Simons 22,900 sh (-84.75%)
» More
Q4 2014

TKMR Guru Trades in Q4 2014

Jim Simons 26,700 sh (+16.59%)
Paul Tudor Jones Sold Out
» More
Q1 2015

TKMR Guru Trades in Q1 2015

Steven Cohen 157,200 sh (New)
John Griffin 1,700,000 sh (New)
PRIMECAP Management 548,603 sh (New)
RS Investment Management 576,140 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TKMR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 9.97
TKMR's Forward P/E is ranked higher than
86% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. TKMR: 9.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.93
TKMR's P/B is ranked higher than
95% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. TKMR: 0.93 )
Ranked among companies with meaningful P/B only.
TKMR' s 10-Year P/B Range
Min: 0.32  Med: 2.51 Max: 261
Current: 0.93
0.32
261
P/S 18.51
TKMR's P/S is ranked lower than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. TKMR: 18.51 )
Ranked among companies with meaningful P/S only.
TKMR' s 10-Year P/S Range
Min: 0.72  Med: 3.66 Max: 37.12
Current: 18.51
0.72
37.12
Current Ratio 9.64
TKMR's Current Ratio is ranked higher than
73% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. TKMR: 9.64 )
Ranked among companies with meaningful Current Ratio only.
TKMR' s 10-Year Current Ratio Range
Min: 0.98  Med: 3.90 Max: 9.64
Current: 9.64
0.98
9.64
Quick Ratio 9.64
TKMR's Quick Ratio is ranked higher than
74% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. TKMR: 9.64 )
Ranked among companies with meaningful Quick Ratio only.
TKMR' s 10-Year Quick Ratio Range
Min: 0.98  Med: 3.90 Max: 9.64
Current: 9.64
0.98
9.64
Days Sales Outstanding 109.56
TKMR's Days Sales Outstanding is ranked lower than
76% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. TKMR: 109.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
TKMR' s 10-Year Days Sales Outstanding Range
Min: 2.76  Med: 43.51 Max: 996.15
Current: 109.56
2.76
996.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.85
TKMR's Price/Net Cash is ranked lower than
68% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. TKMR: 13.85 )
Ranked among companies with meaningful Price/Net Cash only.
TKMR' s 10-Year Price/Net Cash Range
Min: 0.66  Med: 3.10 Max: 37.5
Current: 13.85
0.66
37.5
Price/Net Current Asset Value 11.63
TKMR's Price/Net Current Asset Value is ranked lower than
65% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. TKMR: 11.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TKMR' s 10-Year Price/Net Current Asset Value Range
Min: 0.63  Med: 3.36 Max: 17.46
Current: 11.63
0.63
17.46
Price/Tangible Book 11.29
TKMR's Price/Tangible Book is ranked lower than
74% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. TKMR: 11.29 )
Ranked among companies with meaningful Price/Tangible Book only.
TKMR' s 10-Year Price/Tangible Book Range
Min: 0.59  Med: 3.27 Max: 181.5
Current: 11.29
0.59
181.5
Price/Projected FCF 0.82
TKMR's Price/Projected FCF is ranked higher than
93% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. TKMR: 0.82 )
Ranked among companies with meaningful Price/Projected FCF only.
TKMR' s 10-Year Price/Projected FCF Range
Min: 1.23  Med: 4.72 Max: 16.95
Current: 0.82
1.23
16.95
Price/Median PS Value 5.12
TKMR's Price/Median PS Value is ranked lower than
92% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. TKMR: 5.12 )
Ranked among companies with meaningful Price/Median PS Value only.
TKMR' s 10-Year Price/Median PS Value Range
Min: 0.27  Med: 0.95 Max: 7.73
Current: 5.12
0.27
7.73
Earnings Yield (Greenblatt) (%) -11.52
TKMR's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. TKMR: -11.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKMR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -11.52  Med: 61.15 Max: 3786.2
Current: -11.52
-11.52
3786.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TKM.Canada, I9DN.Germany,
Tekmira Pharmaceuticals Corp was incorporated on October 6, 2005. The Company develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. The Company's internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. In addition, the Company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependence.
» More Articles for TKMR

Headlines

Articles On GuruFocus.com
watching Jun 21 2015 
watching Jun 21 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
John Griffin's New Buys During Q1 2015 May 29 2015 
Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Can Hepatitis B Be A Blockbuster Bug? Jul 01 2015
5 Biotech Stocks On Deck With The FDA Jun 30 2015
Edited Transcript of TKMR presentation 24-Jun-15 6:00pm GMT Jun 30 2015
Sierra Leone's Freetown Set Back In Ebola Eradication Jun 23 2015
Researchers Put Brakes on Study of Tekmira Ebola Drug in West Africa Jun 19 2015
Tekmira says Ebola drug unlikely to work in study Jun 19 2015
Tekmira says Ebola drug unlikely to work in study Jun 19 2015
Tekmira stops adding patients in African study of Ebola drug Jun 19 2015
Tekmira stops adding patients in African study of Ebola drug Jun 19 2015
Tekmira: With Its Ebola Drug Gone, Is It Worth the Risk? Jun 19 2015
Tekmira halts enrollment on Ebola tests; shares fall Jun 19 2015
Tekmira Tumbles On Ominous Signs For Ebola Drug Jun 19 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 19 2015
Tekmira Provides Update on TKM-Ebola-Guinea Jun 19 2015
Tekmira to Present at JMP Securities Life Sciences Conference Jun 18 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 18 2015
Tekmira to Present at JMP Securities Life Sciences Conference Jun 18 2015
Tekmira Pharma downgraded by Maxim Group Jun 15 2015
Dementia drug developer Axovant climbs after $315M IPO Jun 11 2015
Dementia drug developer Axovant climbs after $315M IPO Jun 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK